Frontiers in Microbiology (Nov 2023)

Immune modulation of gut microbiota and its metabolites in chronic hepatitis B

  • Shi-Qin Li,
  • Shi-Qin Li,
  • Yue Shen,
  • Yue Shen,
  • Yue Shen,
  • Jun Zhang,
  • Jun Zhang,
  • Cheng-Zhao Weng,
  • Cheng-Zhao Weng,
  • Sheng-Di Wu,
  • Sheng-Di Wu,
  • Sheng-Di Wu,
  • Wei Jiang,
  • Wei Jiang,
  • Wei Jiang

DOI
https://doi.org/10.3389/fmicb.2023.1285556
Journal volume & issue
Vol. 14

Abstract

Read online

The gut microbiota is a diverse ecosystem consisting of 100 trillion microbiomes. The interaction between the host’s gut and distal organs profoundly impacts various functions such as metabolism, immunity, neurology, and nutrition within the human body. The liver, as the primary immune organ, plays a crucial role in maintaining immune homeostasis by receiving a significant influx of gut-derived components and toxins. Perturbations in gut microbiota homeostasis have been linked to a range of liver diseases. The advancements in sequencing technologies, such as 16S rRNA and metagenomics, have opened up new avenues for comprehending the intricate physiological interplay between the liver and the intestine. Metabolites produced by the gut microbiota function as signaling molecules and substrates, influencing both pathological and physiological processes. Establishing a comprehensive host-bacterium-metabolism axis holds tremendous potential for investigating the mechanisms underlying liver diseases. In this review, we have provided a summary of the detrimental effects of the gut-liver axis in chronic liver diseases, primarily focusing on hepatitis B virus-related chronic liver diseases. Moreover, we have explored the potential mechanisms through which the gut microbiota and its derivatives interact with liver immunity, with implications for future clinical therapies.

Keywords